ADC Therapeutics SA Common Shares
IPOADC Therapeutics | Innovating Science. Inspiring Hope.
Public · Lausanne, Switzerland · Founded 2011 · $501.0M raised
- Headquarters
- Lausanne
- Employees
- 201–500
- Founded
- 2011
- Business Model
- B2B
- Website
- adctherapeutics.com
- Total Funding
- $501.0M
- Last Round
- $276.0M Series EJun 2019
- Rounds
- 6
- Type
- Public
About
ADC Therapeutics is a commercial-stage oncology company pioneering targeted antibody drug conjugate (ADC) therapies, with its FDA-approved ZYNLONTA (loncastuximab tesirine-lpyl) for relapsed or refractory large B-cell lymphoma. The company is advancing its ADC portfolio into earlier lines of hematologic cancers and solid tumors to address significant unmet medical needs.
Summary
ADC Therapeutics SA Common Shares is a Biotech company based in Lausanne, Switzerland, founded in 2011. It has raised $501.0M in total across 6 rounds, most recently a $276.0M Series E round in Jun 2019. Investors include AstraZeneca, Auven Therapeutics and Redmile Group.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2020
Sign up to see all 7 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...